» Articles » PMID: 36835420

DUOX1 Gene Missense Mutation Confers Susceptibility on Type 2 Amiodarone-Induced Thyrotoxicosis

Overview
Journal Int J Mol Sci
Publisher MDPI
Date 2023 Feb 25
PMID 36835420
Authors
Affiliations
Soon will be listed here.
Abstract

Possible triggers and genetic markers involved in pathogenesis of amiodarone-induced thyrotoxicosis (AIT) or amiodarone-induced hypothyroidism (AIH) are currently unknown. This study aimed to analyze the association between polymorphisms in the genes involved in thyroid hormones biosynthesis and metabolism. Thirty-nine consecutive patients with confirmed type 2 amiodarone-induced thyrotoxicosis were enrolled; 39 patients on the same therapy for at least 6 months without thyroid pathology were included as a control group. A comparative study was carried out to determine the distribution and genotypes of polymorphic markers of the (Na)-iodide symporter (NIS) genes (rs7250346, C/G substitution), thyroid stimulating hormone receptor (TSHR) (rs1991517, C/G substitution), thyroid peroxidase (TPO) (rs 732609, A/C substitution), DUOX 1-1 (C/T substitution), DUOX 1-2 (G/T substitution), DUOX 1-3 (C/T substitution), glutathione peroxidase 3 (GPX3) (C/T substitution), glutathione peroxidase 4 (GPX4) (C/T substitution). Statistical analysis was performed using Prism (Version 9.0.0 (86)). This study showed that the risk of AIT2 is 3.18 times higher in the G/T of the DUOX1 gene carriers. This study is the first report of genetic markers associated with amiodarone-related adverse events conducted in humans. The obtained results indicate the necessity for a personalized approach to amiodarone administration.

Citing Articles

[Type 2 amiodarone-induced thyrotoxicosis: prevalence, time and predictors of development].

Ermolaeva A, Fadeev V Probl Endokrinol (Mosk). 2024; 70(3):9-22.

PMID: 39069769 PMC: 11334237. DOI: 10.14341/probl13348.

References
1.
Agoston M, Orsi F, Feher E, Hagymasi K, Orosz Z, Blazovics A . Silymarin and vitamin E reduce amiodarone-induced lysosomal phospholipidosis in rats. Toxicology. 2003; 190(3):231-41. DOI: 10.1016/s0300-483x(03)00188-4. View

2.
Ahmed S, Van Gelder I, Wiesfeld A, Van Veldhuisen D, Links T . Determinants and outcome of amiodarone-associated thyroid dysfunction. Clin Endocrinol (Oxf). 2011; 75(3):388-94. DOI: 10.1111/j.1365-2265.2011.04087.x. View

3.
De Deken X, Wang D, Dumont J, Miot F . Characterization of ThOX proteins as components of the thyroid H(2)O(2)-generating system. Exp Cell Res. 2002; 273(2):187-96. DOI: 10.1006/excr.2001.5444. View

4.
Mosher M . Amiodarone-induced hypothyroidism and other adverse effects. Dimens Crit Care Nurs. 2011; 30(2):87-93. DOI: 10.1097/DCC.0b013e3182052130. View

5.
Dedov I, Melnichenko G, Sviridenko N, Platonova N, Molashenko N, Egorov A . [Diagnostics, treatment, and prevention of iatrogenic iodine-induced thyroid gland diseases]. Vestn Ross Akad Med Nauk. 2006; (2):15-22. View